Avodart is a dual 5-alpha reductase inhibitor that prevents testosterone conversion to dihydrotestosterone (DHT). Dutasteride is also known by its trademark name. It is used for benign prostatic hyperplasia, but it raises the risk of erectile dysfunction and decreases sexual desire.
Dutasteride is useful for the effects of benign prostatic hyperplasia ( BPH); a “enlarged prostate” colloquially known. The overall risk of being diagnosed with prostate cancer is decreased in those who are routinely screened for 5-alpha-reductase inhibitors (finasteride and dutasteride), although there is insufficient evidence to decide whether they have an impact on the risk of death and could raise the likelihood of more severe cases.
This class of drugs raises erectile dysfunction rates (with issues occurring between 5% and 9% after beginning their use). This is related to a lower quality of life, and relationships can cause stress. There is a correlation with decreased sexual appetite as well. It was confirmed that even after discontinuation of the medication, these adverse sexual side effects could continue. Dutasteride has issued an alert from the FDA about an elevated risk of high-grade prostate cancer. Although the potential for positive , negative or neutral improvements to the potential risk of developing dutasteride prostate cancer has not been established, evidence has indicated that the growth and incidence of benign prostate tumors may be temporarily reduced but that early detection of prostate cancer may also be masked. The primary area of concern is for patients who may develop prostate cancer while taking dutasteride for benign prostatic hyperplasia, which in turn may postpone prostate cancer diagnosis and early treatment, thus potentially raising the risk of developing high-grade prostate cancer in these patients.